New Antifungal Drugs, New Approaches and Vaccines

In Vitro Activity of ASP2397 against Aspergillus Isolates with or without Acquired Azole Resistance Mechanisms.

In vitro

11 November 2015

Discovery of a new antifungal agent ASP2397 using a silkworm model of Aspergillus fumigatus infection

17 January 2017

VL-2397 (formerly known as ASP2397) has completed dosing in a Phase 1 clinical trial.

Phase 1

20 October 2017

Activity of pradimicin BMS-181184 against Aspergillus spp.

Phase 1

25 August 1999

Antifungal activity of the pradimicin derivative BMS 181184 in the treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.

17 September 1998

Cloning, sequencing, and characterization of the pradimicin biosynthetic gene cluster of Actinomadura hibisca P157-2

16 May 2007

Pradimicins: a novel class of broad-spectrum antifungal compounds

Phase 1

14 January 1997

VT-1598 has received orphan drug and Fast Track designations for the treatment of Valley Fever

20 October 2017

Phase 2b Results of Viamet’s Oral VT-1161 for the Treatment of Recurrent Vulvovaginal Candidiasis (Presented at IDSOG Annual Meeting)

Phase 2

11 August 2017

In Vitro Antifungal Activity of Nikkomycin Z in Combination with Fluconazole or Itraconazole

16 June 1999